NVCT
Nuvectis Pharma·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 3
Ample Liquidity
Significant Net Income Decline
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVCT
Nuvectis Pharma, Inc.
A biopharmaceutical company developing treatments for serious oncology-related diseases
1 Bridge Plaza, Suite 275, Fort Lee, NJ, 07024
--
Nuvectis Pharma, Inc., was incorporated under the laws of the State of Delaware on July 27, 2020. The Company is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical oncology needs. The company's development strategy adopts a precision medicine-based approach to translate key scientific insights related to carcinogenic drivers, pathway addiction and their cancer-promoting factors into selective, potent and highly selective anticancer drugs. The company believes that these advances lay the foundation for the modern development of targeted therapies, which will enable the discovery and development of anti-cancer therapies based on tumor genetic characteristics rather than tumor histology.
Company Financials
EPS
NVCT has released its 2025 Q3 earnings. EPS was reported at -0.44, versus the expected -0.25, missing expectations. The chart below visualizes how NVCT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
